PC
NBRV

Polar Capital’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Polar Capital’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-120
Closed -$269K – 280
2016
Q1 		$269K Buy
120
+76
+173% +$163K 0.01% 259
2015
Q4 		$104K Buy
+44
New +$107K ﹤0.01% 265

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Polar Capital's NBRV Position: Q2 2016 in Review

Polar Capital sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2016, closing a stake of 120 shares — an estimated $269K sold.

Polar Capital first reported a position in NBRV in Q4 2015 and held it in 2 quarters. The position peaked at $269K in Q1 2016. 20 funds tracked by Wall St. Rank hold NBRV as of Q2 2016.

  • Polar Capital reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2016 after selling out during the quarter.
  • Polar Capital sold 120 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2016, an estimated $269K.
  • Polar Capital first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2015 and held it in 2 quarters.
  • Polar Capital's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $269K in Q1 2016.
  • 20 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2016.

Based on Polar Capital's 13F filing for Q2 2016, filed 15 Aug 2016.